Travere Therapeutics, Inc. cotiza a 52.13 USD y tiene una capitalización bursátil de $4.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.10 | $0.05 | $0.37 |
| Estimado | $0.49 | $0.32 | $-0.06 | $0.37 |
| Sorpresa | — | -131.3% | +183.3% | +0.0% |
| Métrica | TVTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 97.9% | 57.0% | +40.9% |
| Operating Margin | -12.8% | -38.6% | +25.8% |
| Net Margin | -5.2% | -33.6% | +28.4% |
| FCF Margin | — | -13.9% | — |
| ROE | -22.3% | -40.4% | +18.1% |
| ROA | -4.2% | -32.0% | +27.8% |
| Current Ratio | 2.74 | 2.84 | -0.10 |
| Debt / Equity | — | 0.28 | — |